Heparin Test Kits

Anti XAE Assay Kit, 100 determinations XAE 100

Description

Heparin test kits designed for USP and EP compliant testing of Anti-IIa and Anti-Xa activity of heparin and 

LMW heparin including Enoxaparin Sodium. Supplied by Provision Kinetics, USA.

The versatile, highly reliable kits have a wide range of uses including pharmaceutical applications like quality 

control or medical device and research testing, as well as test adaptations for heparin-coated devices.

Application

The Kinetichrome heparin test kits are designed for the chromogenic measurement of the anti-factor IIa (thrombin) 

and/or anti-factor Xa activity in samples containing heparin, low molecular weight heparin and related molecules 

with thrombin and/or factor Xa inhibitor activity.

A distinctive feature of the Kinetichome product line is that these kits are designed and optimized for activity 

measurements with buffer as the reaction medium, rather than plasma. Thus, the Kinetichrome heparin test kits 

are ideally suited for research, industrial, and pharmacopeial test applications where buffer is the specified 

test medium.

Information

New heparin assay guidelines from European Pharmacopeia.

The 8th edition of the European Pharmacopoeia, supplement 8.3, issued on 1st July 2014 and coming into effect 

from 1st January 2015 has new guidelines on chromogenic assays for anti-IIa and anti-Xa activities

Provision Kinetics has modified their Xa Heparin test kits in order to FULLY conform with the EP directives – accordingly, 

the XAE-100 and XAE-200 Heparin Test Kits are available now. The IIa Heparin Test Kits are already compatible the ruling.

Please note

The kits have 100 and 200 determinations when in optimal conditions on an automated haemostasis instrument, if you 

are using the manual test method(s) on a lab bench it is more realistic to expect about 50 determinations from a 100 

determination kit and 100 from a 200 determination kit.

We have programs/applications available for major haemostasis instrument platforms including:

Instrumentation Laboratory (IL) product line

Diagnostica Stago (Stago) line

Sysmex line (Siemens in the US)

Summary and principle

Thrombin (Factor IIa) is the terminal enzyme in the classical coagulation cascade, where it plays roles in both the fibrin 

deposition and platelet activation processes of blood coagulation. Unfractionated Heparin (UFH) and Low Molecular 

Weight Heparin (LMW-H) inhibit blood coagulation via initial binding of these molecules to Antithrombin (AT), followed 

subsequently by the AT-heparin complex inhibiting Factor Ila. In buffer, this same “Anti-lla” activity of heparin can be 

foJlowed enzymatically by means of a chromogenic peptide substrate which, upon hydrolysis by residual factor IIa, 

provides a chromophore (405 nm) whose measure is inversely proportional to the initial amount of heparin present in 

the test sample. The paranitroanaline (pNA) chromophore generated by the residual factor lIa can be measured either 

kinetically or by an acid-stopped end-point method.

Schematically, the procedure is carried out as follows:

AT + heparin → (AT-heparin)

[AT-heparin) + IIa (known excess) → Ila (residual) + IIa-AT-heparin (inactive)

IIa (residual) + IIa Substrate (colorless) → pNA chromophore (405 nm) + peptide